≥99% HPLCPre-filled pen

AC-Semax-NH2

Name: AC-Semax-NH2
Brand: Dripfy
Availability: InStock

What it is?

AC-Semax-NH2 is a stabilised synthetic analogue derived from ACTH fragment research, positioned for neuroprotective and cognitive-support signalling. It is commonly used in protocols targeting attention, memory, and neurological resilience markers.

Dripfy Advantage

Neurotrophic signalling support: Associated with stimulation of neurotrophic factor pathways relevant to neuroplasticity and cognitive performance.
CNS recovery alignment: Positioned to support central nervous system recovery signalling following stress, fatigue, or high cognitive load.
Neuroprotection profile: Frequently framed around protective signalling against oxidative and metabolic stress in neuronal models.
Cerebral perfusion interface: Often discussed in cognitive frameworks where cerebral blood-flow-related signalling is relevant to performance endpoints.

Clinical Applications & Therapeutic Potential

Cognitive performance endpoints: Potential support for improved attention, processing, and task-performance measures in structured protocols.
Memory and learning markers: Potential improvements in memory formation and retention endpoints via neuroplasticity-related signalling.
Neuroprotective frameworks: Positioned for long-term brain health protocols focused on stress resilience and neuronal protection markers.
Mood and anxiety-associated outcomes: Potential support for mood stability and anxiety reduction markers, context-dependent and protocol-specific.

Composition & Formulation

Peptide Content: 5 mg Semax
Vehicle: Proprietary pH-balanced buffer solution
Delivery System: Pre-filled, multi-dose, closed-system pen
Total Volume: 3 mL
Purity: ≥99% by HPLC/MS

€413

Order by email

Submit an enquiry and we arrange the consultation, physician review and shipping. Physician recommendation required; not medical advice.

Purity: ≥99%
Form: Pre-filled pen
Download Certificate of Analysis: Certificate of Analysis available on request

Important medical notice

A physician recommendation is mandatory before use.
The information on this website is educational only and is not medical advice, diagnosis, or treatment.
Always consult a qualified physician before starting any peptide.
Dosing is individualised and determined by your treating physician.

Peptide Practice Guide

Each card summarises what the peptide is studied for and its evidence strength. It is not a recommendation. Dosing and suitability are decided by your physician.

AC-Semax-NH2

Investigational synthetic neuroprotective and nootropic peptide (ACTH(4-10) analogue) · Pre-filled pen

C· Emerging evidence

Semax is a synthetic peptide based on a fragment of the hormone ACTH (the ACTH(4-10) sequence), modified so that it acts on the nervous system without the classic hormonal actions of ACTH. It has been studied, largely in Russia, for neurotrophic signalling — including brain-derived neurotrophic factor (BDNF) — and for protective effects on neurons under oxidative and metabolic stress. These remain research-stage observations and should not be read as proven cognitive benefits.

Studied use areas

Attention, memory and mental-performance endpoints
Neuroprotective signalling under oxidative or metabolic stress
Central nervous system recovery after fatigue or high cognitive load
Cognitive resilience in demanding or high-stress contexts

Safety & status

Investigational peptide; not approved by EMA or MHRA, with most clinical experience coming from regional (Russia/CIS) use, so robust long-term safety data are lacking.
Administration (commonly intranasal or injectable) belongs under physician supervision with individual assessment.
Effects on neurological or psychiatric conditions and medications are not well characterised; share full medical history with the treating physician.

⚕ Clinical note: This card is educational and is not medical advice, a diagnosis, or a treatment recommendation. AC-Semax-NH2 is investigational; any consideration of it must take place under qualified physician supervision, with dosing and suitability determined individually by the treating physician.

Evidence: Limited human data, mostly from regional (Russia/CIS) clinical use; not EMA/MHRA approved. · References: Peer-reviewed neuroprotection and nootropic research literature; Regional (Russia/CIS) clinical studies on Semax; EMA/MHRA regulatory status information